Eli Lilly agreed to acquire LimmaTech Biologics — a Swiss clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases — for up to USD 780 m in cash, inclusive of an upfront payment and additional potential
Tags :Vischer
VIscher appointed managing associates Basile Walder, Elias Mühlemann and Luzius Zumstein to head the firm’s startup desk. The trio succeeds partners Christian Wyss, Damien Conus and Gian-Andrea Caprez, previous heads of the desk.
Vischer advised Burckhardt of Switzerland, a Basel-based specialist in perforation and fibrillation for technical textiles and plastic film processing, on its partnership with Indian manufacturer R.K. Texparts. The collaboration in question will consolidate part
Vischer advised FimmCyte, a Swiss biotech developing targeted immunotherapies for chronic fibro-inflammatory diseases, in connection with its research collaboration and option-to-license agreement with Gedeon Richter, a pharmaceutical company specialised in women’s health, with headquarters
Vischer advised Virometix, a clinical-stage biotechnology company developing fully synthetic vaccines, throughout completion of a $15m financing round from existing shareholders. The company will direct all proceeds from the round to supporting clinical and development
Vischer advised Oncobit as the Swiss specialist in precision oncology entered a strategic partnership with ID Solutions, a French company specialising in oncologic diagnostic solutions. The two companies aim at developing a new generation of
Investment company Afinum completed the acquisition of a majority stake in Zurich-based IT company Ergon Informatik. In connection with the deal, Vischer represented Afinum, while Niederer Kraft Frey (NKF) advised Zürcher Kantonalbank, as mandated
Vischer advised Relief, now MindMaze Therapeutics Holding, in connection with its acquisition of all shares in NeuroX Group, against issuance of new MMTX shares to complete their business combination by way of reverse merger.
Vischer advises Oculis Holding, as the globally active biopharmaceutical company announced the pricing of offerings for an aggregate of 5,432,098 of its ordinary shares. The stocks value at $20.25 per unit, for total gross proceeds of USD 110
Swedish trading company Bufab Group completed the acquisition of Novia Group – a German-based provider of global sourcing solutions and engineering services operating across Germany, Switzerland, China, and Vietnam – from the German investment company Family Trust.
